Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.

Mueller, Kelly L.

Madden, Julie M.

Zoratti, Gina L.

Kuperwasser, Charlotte.

List, Karin.

Boerner, Julie L.

2012

Description
  • Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown clinical efficacy in lung, colon, and pancreatic cancers. In lung cancer, resistance to EGFR TKIs correlates with amplification of the hepatocyte growth factor (HGF) receptor tyrosine kinase Met. Breast cancers do not respond to EGFR TKIs, e... read more
This object is in collection Permanent URL Citation
  • Mueller, Kelly, Julie M. Madden, Gina L. Zoratti, Charlotte Kuperwasser, Karin List, and Julie L. Boerner. "Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met." Breast Cancer Research 14, no. 6 (8, 2012): 1-11.
ID:
s1784z650
To Cite:
DCA Citation Guide    EndNote